Zhan M - Search Results

1

Adverse events identified by the global trigger tool at a university hospital: A retrospective medical record review.

Hu Q, Wu B, Zhan M, Jia W, Huang Y, Xu T. Hu Q, et al. Among authors: zhan m. J Evid Based Med. 2019 May;12(2):91-97. doi: 10.1111/jebm.12329. Epub 2018 Dec 3. J Evid Based Med. 2019. PMID: 30511516

2

Development of a trigger tool for the detection of adverse drug events in Chinese geriatric inpatients using the Delphi method.

Hu Q, Qin Z, Zhan M, Wu B, Chen Z, Xu T. Hu Q, et al. Among authors: zhan m. Int J Clin Pharm. 2019 Oct;41(5):1174-1183. doi: 10.1007/s11096-019-00871-x. Epub 2019 Jun 28. Int J Clin Pharm. 2019. PMID: 31254152

3

Validating the Chinese geriatric trigger tool and analyzing adverse drug event associated risk factors in elderly Chinese patients: A retrospective review.

Hu Q, Qin Z, Zhan M, Chen Z, Wu B, Xu T. Hu Q, et al. Among authors: zhan m. PLoS One. 2020 Apr 28;15(4):e0232095. doi: 10.1371/journal.pone.0232095. eCollection 2020. PLoS One. 2020. PMID: 32343726 Free PMC article.

4

Sitagliptin in the treatment of type 2 diabetes: a meta-analysis.

Zhan M, Xu T, Wu F, Tang Y. Zhan M, et al. J Evid Based Med. 2012 Aug;5(3):154-65. doi: 10.1111/j.1756-5391.2012.01189.x. J Evid Based Med. 2012. PMID: 23672222 Review.

5

Cost-effectiveness analysis of neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced esophageal squamous cell carcinoma based on the NEOCRTEC5010 trial.

Zhan M, Zheng H, Yang Y, Xu T, Li Q. Zhan M, et al. Radiother Oncol. 2019 Dec;141:27-32. doi: 10.1016/j.radonc.2019.07.031. Epub 2019 Aug 17. Radiother Oncol. 2019. PMID: 31431378 Clinical Trial.

6

Cost-effectiveness analysis of the addition of bevacizumab to temozolomide therapy for the treatment of unresected glioblastoma.

Chen Z, Zhan M, Tian F, Xu T. Chen Z, et al. Among authors: zhan m. Oncol Lett. 2020 Jan;19(1):424-430. doi: 10.3892/ol.2019.11099. Epub 2019 Nov 14. Oncol Lett. 2020. PMID: 31897155 Free PMC article.

7

Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study.

Zhan M, Xu T, Zheng H, He Z. Zhan M, et al. Front Public Health. 2022 Mar 2;10:790225. doi: 10.3389/fpubh.2022.790225. eCollection 2022. Front Public Health. 2022. PMID: 35309225 Free PMC article.

8

Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial.

Zhan M, Zheng H, Xu T, Yang Y, Li Q. Zhan M, et al. Lung Cancer. 2017 Aug;110:1-6. doi: 10.1016/j.lungcan.2017.05.012. Epub 2017 May 12. Lung Cancer. 2017. PMID: 28676211 Clinical Trial.

9

Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin in the first-line setting for Chinese patients with metastatic nasopharyngeal carcinoma.

Jin C, Zheng H, Zhan M, Wen F, Xu T. Jin C, et al. Among authors: zhan m. Eur Arch Otorhinolaryngol. 2020 Feb;277(2):577-584. doi: 10.1007/s00405-019-05714-z. Epub 2019 Nov 12. Eur Arch Otorhinolaryngol. 2020. PMID: 31720816 Clinical Trial.

10

Cost-effectiveness analysis of ramucirumab treatment for patients with hepatocellular carcinoma who progressed on sorafenib with α-fetoprotein concentrations of at least 400 ng/ml.

Zheng H, Qin Z, Qiu X, Zhan M, Wen F, Xu T. Zheng H, et al. Among authors: zhan m. J Med Econ. 2020 Apr;23(4):347-352. doi: 10.1080/13696998.2019.1707211. Epub 2020 Jan 6. J Med Econ. 2020. PMID: 31856618 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,281 results

Search Page

Filters